Shares of Acer Therapeutics Inc (NASDAQ:ACER) passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $11.15 and traded as high as $2.93. Acer Therapeutics shares last traded at $2.93, with a volume of 1,309 shares.
ACER has been the subject of a number of recent analyst reports. Zacks Investment Research lowered Acer Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th. ValuEngine raised Acer Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective (down from $55.00) on shares of Acer Therapeutics in a report on Wednesday, June 26th. Needham & Company LLC lowered Acer Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Finally, Raymond James lowered Acer Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, June 25th. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Acer Therapeutics has an average rating of “Hold” and an average price target of $26.29.
The business has a fifty day moving average of $2.98 and a 200-day moving average of $10.96.
A number of hedge funds and other institutional investors have recently modified their holdings of ACER. BlackRock Inc. boosted its stake in Acer Therapeutics by 1,560.8% during the 2nd quarter. BlackRock Inc. now owns 331,553 shares of the biopharmaceutical company’s stock valued at $1,293,000 after purchasing an additional 311,590 shares in the last quarter. Sphera Funds Management LTD. bought a new position in Acer Therapeutics during the 1st quarter valued at $1,215,000. Wedbush Securities Inc. bought a new position in Acer Therapeutics during the 2nd quarter valued at $94,000. Citadel Advisors LLC bought a new position in Acer Therapeutics during the 2nd quarter valued at $67,000. Finally, Vanguard Group Inc. boosted its stake in Acer Therapeutics by 5.4% during the 2nd quarter. Vanguard Group Inc. now owns 277,963 shares of the biopharmaceutical company’s stock valued at $1,084,000 after purchasing an additional 14,337 shares in the last quarter. 24.44% of the stock is owned by hedge funds and other institutional investors.
About Acer Therapeutics (NASDAQ:ACER)
Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders.
Read More: How to invest using market indexes
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.